While most people have never heard of granulomatosis with polyangiitis, this rare inflammatory disease has a nasty habit of attacking the ears—along with the sinuses, lungs, and kidneys. For a 34-year-old man experiencing unexplained hearing loss, this diagnosis probably wasn’t on his radar. Most people assume ear problems are just ear problems. They’re not always.
GPA, previously called Wegener’s granulomatosis, is an uncommon systemic inflammatory vasculitis. The numbers tell an unsettling story. ENT symptoms occur in 70 to 99 percent of patients. Hearing loss affects somewhere between 23 and 56 percent of cases. Sometimes it’s mild. Sometimes it’s profound and irreversible. The disease doesn’t ask permission. Healthcare workforce shortages exacerbate the difficulty in providing timely diagnosis and treatment for conditions like GPA, where early intervention is crucial.
The mechanism is brutal. Vasculitic inflammation occludes capillaries, thickens vessel walls, causes hemorrhaging in delicate inner ear structures like the stria vascularis and spiral ligaments. Both conductive and sensorineural hearing loss can occur. The conductive type often stems from sinonasal inflammation and chronic ear infections. The sensorineural variety? It frequently shows poorer recovery rates. Not great odds.
Here’s the frustrating part. Hearing loss can show up months before other characteristic symptoms appear. That means diagnosis gets delayed. A lot. Meanwhile, the patient deals with fatigue, weight loss, sinusitis, fever, night sweats—vague complaints that could be anything.
Head and neck symptoms eventually appear in up to 70 to 100 percent of cases. Nasal pain, crusting, nosebleeds, earaches, fluid drainage from the ear. Some patients develop subglottic stenosis, affecting 1 to 23 percent. The bridge of the nose can literally lose height as cartilage weakens. Cartilage damage isn’t limited to the nose—it can occur wherever granulomas form and destroy healthy tissue.
Diagnosis requires blood work: full blood count, renal profile, ESR, CRP, and the telltale cANCA titre. Most GPA patients test positive for PR3-ANCA antibodies. Urine dipstick screens for kidney involvement. Chest X-rays and CT scans check for organ damage.
But here’s the catch—guidelines for autoimmune inner-ear disease lack clarity. Serologic testing remains inconsistent. Treatment often becomes empiric, a calculated guess. And irreversible hearing loss hangs in the balance when diagnosis drags on. The ears weren’t just the problem. They were the warning. Even during remission, patients need continuous medical monitoring because GPA can relapse without notice.
